Professional Documents
Culture Documents
Tumor antigens
Effectors mechanisms in anti-tumor
immunity
Mechanisms of tumor evasion of the
immune system
Immunotherapy for tumors
Causative agents
Spontaneous
Tumour
induction
Genetic
Virus-induced
abnormalities (XP)
(HepC, EBV, HPV)
Immunosuppression
Tumors sometime express mutant proteins or express
proteins that are normally sequestered: Tumor antigens
Some tumors are antigenic in the host where they arise
because of abnormal expression of self proteins
How do cancer cells differ from
normal?
Clonal in origin
Deregulated growth and lifespan
Altered tissue affinity
Resistance to control via apoptotic signals
Change in surface phenotype and markers
Structural and biochemical changes
Presence of tumour-specific antigens
Immunosurveillance
Normal Cell
Mutation or virus
Transformed Analogous to a
(cancerous) but also bacterial
population being
becomes antigenic treated with
antibiotics such
Immune that antibiotic-
Mutation resistant
mutants take-
response over the
population
Transformed
Dead (cancerous) but
escapes from immune
response
Is this a common mechanism for tumor progression?
Probably not (but there may be some striking exceptions).
Evidence in Support of
Immunosurveillance
based cancer-therapy.
Tissue -Specific Tumor Antigens Used in
Clinico pathologic Analysis of Tumors
B lymphocytes B cell leukemias CD10 (CALLA),
and lymphomas Immunoglobulin
B Th
Th cells educate
other T/B cells
CTL CTL
APC recruits T cells
Broken up to able to recognise CTL recognise
release antigens tumour antigens and destroy other
T tumour cells
APC T
Effectors mechanisms against
cancer
NKT
CD4
CTL
NK NK CTL NK
CTL CD4 CTL
CTL
FasL
Perforin
Granzyme B TCR
Fas (CD95)
C
l
a
s
s
I
+
IR-Mediated Tumour
Elimination
NKT
NKT NKT
NK T T NK CTL
NK NK CD4
NK CTL
CTL
CD4
CTL
CXC10-12
IFN
IFN M
LN CXC10-12 M
DC IFN DC M
Lack of
Neo-antigens
Escape from immunosurveillance
Lack of
class I MHC
Escape from immunosurveillance